XML 109 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1

Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details) - USD ($) $ in Thousands	3 Months Ended													12 Months Ended
	Dec. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2019	Sep. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue														$ 17,157	$ 10,287	$ 63,175
Milestone revenue recognition														Cash is generally received within 30 days of milestone achievement.
GSK
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue														$ 17,200	10,300	$ 63,200
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue													$ 1,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | IND clearance from the FDA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue											$ 4,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Phase 2 clinical trial initiation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue									$ 3,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue							$ 5,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue						$ 5,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue					$ 10,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue					$ 5,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue				$ 10,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First BLA approval - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue			$ 20,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First MAA approval - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue			$ 10,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First BLA approval - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue		$ 20,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														5,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First MAA approval - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														10,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | First commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														15,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Second commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														25,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Third commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														50,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Fourth commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														75,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Milestones recognized through December 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue														93,000
GSK | Anti-PD-1 (Jemperli/Dostarlimab) | Milestones that may be recognized in the future
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														180,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue												$ 1,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | IND clearance from the FDA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue										$ 4,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Phase 2 clinical trial initiation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue								$ 3,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Phase 3 clinical trial initiation - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue	$ 5,000														$ 5,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Phase 3 clinical trial initiation - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														5,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first BLA - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														10,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first MAA - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														5,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first BLA - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														10,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First BLA approval - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														20,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First MAA approval - first indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														10,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First BLA approval - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														20,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Filing of the first MAA - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														5,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First MAA approval - second indication
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														10,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | First commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														15,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Second commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														25,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Third commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														50,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Fourth commercial sales milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														75,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Milestones recognized through December 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue														13,000
GSK | Anti-TIM-3 (GSK4069889A/Cobolimab) | Milestones that may be recognized in the future
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones that may be recognized in the future														$ 260,000

X

- Definition

Revenue Recognition, Milestone Method, Contingent

+ References

No definition available.

+ Details

Name:	anab_RevenueRecognitionMilestoneMethodContingent
Namespace Prefix:	anab_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Description of effect, from relationship that timing of satisfaction of performance obligation has on timing of payment, on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and on obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

+ Details

Name:	us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfBiologicsLicenseApplicationFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfMMAFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfBiologicsLicenseApplicationSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstBiologicsLicenseApplicationApprovalDMMRECMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstMarketingAuthorizationApplicationApprovalFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstBiologicsLicenseApplicationApprovalSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FilingOfMMASecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstMarketingAuthorizationApplicationApprovalSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FirstCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_SecondCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_ThirdCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_FourthCommercialSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_CumulativeMilestonesRecognizedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=anab_MilestonesYetToBeRecognizedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: